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Background: With the recent attention to evidence-based medicine in psychiatry, a number of treatment
guidelines for bipolar disorders have been published. This survey investigated prescribing patterns and predictors
for guideline disconcordance in the acute treatment of a manic and mixed episode across mainland China.
Methods: The pharmacological treatments of 2828 patients with a recent hypomanic/manic episode or mixed state
were examined. Guidelines disconcordance was determined by comparing the medication(s) patients were
prescribed with the recommendation(s) in the guidelines of the Canadian Network for Mood and Anxiety
Treatments.
Results: The most common pattern of pharmacological treatments for an acute manic or mixed episode was a
mood stabilizer plus an atypical antipsychotic (n = 1345, 47.6%), and the rate of guideline-disconcordant treatments
was 11.1%. The patients who were treated in general hospitals were more likely to receive guideline-disconcordant
treatments than those who were treated in psychiatric hospitals, with an OR of 1.84 (95% CI 1.44-2.36). Similarly, the
patients with a mixed episode at study entry were more likely to receive guideline-disconcordant treatments than
those with a manic episode, with an OR of 1.69 (95% CI 1.22-2.35). In contrast, the patients with a longer duration
of disease (>5 years) were less likely to receive guideline-disconcordant treatments than those with a short duration,
with an OR of 0.47 (95% CI 0.36-0.60).
Conclusions: In mainland China, the disconcordance with treatment guidelines for a most recent acute manic or
mixed episode was modest under naturalistic conditions. The higher risk for disconcordance in general hospitals
than in psychiatric hospitals suggests that special education based on treatment guidelines to practitioners in
general hospitals is necessary in order to reduce the risk for disconcordant treatments.
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There is growing recognition that bipolar disorder (BPD)
is common, with bipolar disorder type I (BP-I) and type II
(BP-II) affecting about 2% of the world’s population and
subthreshold forms of the disorder affecting another 2%
[1,2]. BPD is responsible for the loss of disability-adjusted
life years (DALYs) more than all forms of cancers or major
neurological conditions, primarily because of its early on-
set and chronicity across the life span [2]. The recurrent
nature of manic and depressive episodes often leads to
high direct and indirect health care costs [3,4]. Moreover,
BPD is also a leading cause of premature mortality due to
suicide and comorbid medical conditions such as diabetes
and cardiovascular diseases [5,6].
There is evidence that greater provider adherence to
treatment guideline recommendations was associated with
a greater reduction in symptoms and greater improvement
in the outcome of diseases [7,8]. For this reason, a number
of treatment guidelines have emerged to aid clinicians to
make clinical decisions for the treatment of patients with
BPD. These practice guidelines include, but not limited to,
the guideline of the American Psychiatric Association [9],
the British Psychological Society [10], the Chinese Medical
Association [11], the World Federation of Societies of Bio-
logical Psychiatry [12-14], the Health Ministry of Singapore
[15], and the Canadian Network for Mood and Anxiety
Treatments (CANMAT) and the International Society for
Bipolar Disorders (ISBD) [16].
Although the timeline of these guidelines has spread
more than a decade, recent advances in pharmacological
treatment for patients with acute mania remain quite
modest [16,17], lithium, valproate/divalproex, carbamaze-
pine, and antipsychotics have been the cornerstones for
the acute treatment of mania for decades. More import-
antly, treatment-disconcordance in acute mania has con-
tinuously been reported. In a previous survey with 224
mood episodes in 84 outpatients with BPD from the UK,
the rate of guidelines concordance was 81% for manic
episode [18]. A large-scale and prospective study in
964 outpatients with BPD from the US reported that
the guideline-concordant treatments for hypomanic/
manic and mixed episode(s) were 82% [19]. However, a
more recent study in 113 individuals with BPD who were
referred to a Mental Health Centre from the community
found that the rate of guideline-concordant treatment
based on CANMAT& ISBD guidelines for hypomania was
only 32% [20].
There was no update on treatment-guidelines for bipolar
disorder in mainland China since 2007. Until now there
has never been a study on the guidelines concordance for
the treatment of BPD in China. This report is to present
the data of a national survey (Bipolar Mania Pathway Survey,
BIPAS) on the acute treatment of a recent manic or mixed
episode in routine clinical practice in mainland China.Methods
Participants
The BIPAS study was conducted in 26 sites (15 psychi-
atric hospitals and 11 psychiatric departments of general
hospitals) across mainland China from the November of
2012 to the January of 2013. All procedures were reviewed
and approved by the institutional review boards of Shang-
hai Mental Health Center and other participating institu-
tions. Written informed consents were obtained from
each participant before any study-related procedure was
performed. Diagnosis of bipolar disorder was ascertained
with ICD-10 (International Classification of Disease – 10
Edition) diagnostic criteria for BPD by a review of medical
records. Both inpatients and outpatients who presented
with an acute manic/mixed episode or in remission were
consecutively screened for this study without consider-
ation of age limitation or other exclusion criteria.
Clinical assessments
All patients who were enrolled in the study received a
single-round survey. During the screening visit, variables
including gender, hospital category, mood state at first on-
set and at study entry, current co-morbidity with mental
disorders and/or physical disorders, family history of a
mental disorder(s), the age at study entry and at first on-
set, the duration of BPD, and the number of episodes in
past year were obtained from patients, their family mem-
bers, and medical records by research psychiatrists and re-
search assistants. The prescribing information (name of
psychotropic agents) for a recent manic/mixed episode
was retrospectively obtained from patients’ medical records.
The collected psychotropic agents included mood stabi-
lizers, antipsychotics, antidepressants, Chinese medicine,
and benzodiazepines for treating mental symptom. Medi-
cations for dealing with physical diseases or side effects re-
lated to psychotropic agents were not collected.
Disconcordance determination
Recommendations for pharmacological treatment of acute
mania by the CANMAT and ISBD guidelines [16] were
used to determine a treatment(s) as guideline concordance
or disconcordance. The use of these guidelines as “stand-
ard” was justified because they were commonly recom-
mended during continuing medical education and clinical
practice in mainland China. Among the available psycho-
tropic agents for bipolar mania in clinical practice in
mainland China, mood stabilizer (lithium and valproate)
monotherapy and atypical antipsychotic monotherapy
(risperidone, olanzapine, quetiapine, aripiprazole and
ziprasidone) were considered as the first-line treatments;
adjunctive therapy of atypical antipsychotics with lithium
or valproate, and monotherapy of carbamazepine and halo-
peridol as the second-line treatments; and lithium plus val-
proate, and monotherapy of chlorpromazine and clozapine
Table 1 Demographics and clinical characteristics of








Mood state at study entry
-Hypomanic/manic episode 2520 89.1
-Mixed episode 308 10.9
Mood state at first onset
-Hypomanic/manic episode 1925 68.1
-Depressive episode 903 31.9
Current co-morbidity
-Mental disorders 99 3.5
-Physical disorders 203 7.2
Family history of mental disorders 582 20.6
Median IQR
Age at study entry (years) 24.0 19.0-32.0
Age at first onset (years) 32.0 24.0-44.0
Duration of disease (years) 5.0 2.0-12.0
Number of episodes in past year 1.0 1.0-2.0
Table 2 Patterns of pharmacological treatments in
patients with acute manic and mixed episodes
Treatment patterns N %
No agent 209 7.4
Monotherapy 622 22.0
MS 275 9.7
AP (AAP and TAP) 245 8.7
AD 55 1.9
Other agent 47 1.7
Two drugs combination 1653 58.5
MS + AAP 1345 47.6
Combination with at least one agent
recommended in guidelines
305 10.8
No treatment following the guidelines 3 0.1
Three or four drugs combination 344 12.2
MS(s) + AAP(s) 73 2.6
Combination with at least one agent
recommended in guidelines
271 9.6
MS mood stabilizers, AP antipsychotic, AAP atypical antipsychotic (risperidone,
olanzapine, quetiapine, aripiprazole, and ziprasidone), TAP typical antipsychotic
(chlorpromazine, clozapine and haloperidol), AD antidepressant, Other agent
Chinese medicine, benzodiazepine and unknown.
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cological treatment with at least one agent or combin-
ation recommended in CANMAT and ISBD guidelines
was considered as guidelines concordance (without a
sequential consideration of treatment options as first-
line agents, second-line agents, and third-line agents).
Therefore, other treatment option(s) was considered as
guidelines disconcordance.
Statistical analysis
Demographics characteristics, clinical features and treat-
ment options for a recent depressive episode were analyzed
with descriptive statistics. A conditional logistic regression
with stepwise method among variables was used to study
independent predictors for guidelines disconcordance. All
candidate variables entered the model were categorical var-
iables. Continuous variables were divided into categories as
their medians. Given the exploratory nature of the study,
statistical significance was set at α = 0.05, two-tailed with-
out adjustment for multiple comparisons.
The variables analyzed in the regression model included
gender (male vs. female), hospital category (psychiatric vs.
general), mood state at first onset (hypomanic/manic epi-
sode vs. depressive episode), mood state at study entry
(hypomanic/manic episode vs. mixed episode), current co-
morbidity with mental disorders (no vs. yes), current co-
morbidity with physical illness (no vs. yes), a family history
of mental disorder(s) (no vs. yes), the age at study entry
(≤32 years vs. >32 years), the age at first onset (≤24 years
vs. >24 years), the duration of disease (≤5 years vs. >5 years),
and the number of episodes in past year (≤1 time vs. >1
time).
Results
Demographics and clinical characteristics
Totally, 3906 participants with BPD were screened for
this survey. After excluding patients with a recent de-
pressive episode, 2828 patients with a recent hypomanic,
manic, or mixed episode were enrolled into the present
study. The majority of patients had a recent hypomanic
or manic episode and the first hypomanic or manic epi-
sode, and was treated in psychiatric hospitals (Table 1).
Most patients did not have current mental or physical
comorbidity, or a family history of mental disorders. The
median age at the study entry was 32 years old. The me-
dian age at the onset of first mood episode was 24 years
old. The median duration of BPD was 5 years. The me-
dian number of mood episodes in the past year was one
episode (Table 1).
Patterns of pharmacological treatment for acute manic
and mixed episodes
As shown in Table 2, of the 2828 patients, 1653 (58.5%)
patients received treatment with two-drug combination
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the most commonly prescribed treatment (n = 1345, 47.6%).
The second most commonly prescribed treatment was
monotherapy (n = 622, 22.0%), which included mood
stabilizer monotherapy (n = 275, 9.7%), antipsychotic
monotherapy (n = 245, 8.7%), antidepressant monotherapy
(n = 55, 1.9%) and other agent monotherapy (n = 47,
1.7%). Meanwhile, 344 (12.2%) patients received the com-
bination of three or four psychotropic agents (n = 344,
12.2%), and 209 (7.4%) patients did not receive any psy-
chotropic agent (Table 2).
Rate of guideline-disconcordant treatments in acute
manic and mixed episodes
As shown in Table 2, 314 (11.1%) patients did not take any
agent recommended in CANMAT guidelines for acute
mania/hypomania, which was considered as guidelines dis-
concordance. The most common treatment of guideline-
disconcordance was non-pharmacological treatment (7.4%),
antidepressant monotherapy (1.9%), and other agent mono-
therapy (1.7%). If the monotherapy of a mood stabilizer or
an atypical antipsychotic as well as the combination therapy
of a mood stabilizer(s) plus an atypical antipsychotic(s)
were strictly considered to be guideline-concordant, the
rate of guidelines disconcordance would increase to
31.5%.
Predictors of guideline-disconcordant treatments in acute
manic and mixed episodes
Among the 11 variables considered for logistic regres-
sion analysis, 3 of them including hospital category,
mood state at study entry, and duration of disease
remained in the model as independent risk factors for
guidelines disconcordance. The patients who were
treated in general hospitals were more likely to receive
guideline-disconcordant treatment than patients treated
in psychiatric hospitals with an OR of 1.84 (95% CI 1.44-
2.36). Similarly, those patients with a mixed episode at
study entry were also more likely to receive guideline-
disconcordant treatment than their counterparts with a
manic episode at study entry, with an OR of 1.69 (95% CI
1.22-2.35). In contrast, patients with a longer duration of
BPD (>5 years) was less likely to receive guideline-
disconcordant treatments than their counterparts with a
shorter duration of equal or less than 5 years, with an OR
of 0.47 (95% CI 0.36-0.60) (Table 3).Table 3 Predictors for guideline-disconcordant treatments
in patients with acute manic and mixed episodes
Predictors Wald χ2 P-value OR 95% CI
General hospitals 23.89 0.000 1.84 1.44-2.36
Mixed episode at study entry 9.77 0.000 1.69 1.22-2.35
Duration of disease (>5 years) 33.24 0.000 0.47 0.36-0.60Discussion
To our knowledge, this is the first national survey to in-
vestigate the current practice of pharmacological treat-
ments and guidelines concordance for an acute mania or
mixed episode in mainland China. The inclusion of both
inpatients and outpatients from both psychiatric hospitals
and general hospitals increase the generalizability of this
study. According to the CANMAT and ISBD guideline
recommendations without considering sequenced treat-
ment alternatives, the disconcordant rate with guidelines
in the present study was 11.1% (Table 2).
The disconcordant rate with the guidelines in our sur-
vey was lower compared with that previously reported in
a Systematic Treatment Enhancement Program for Bipo-
lar Disorder (STEP-BD) study from United States [19],
in which the disconcordant rate was about 18% for
hypomanic/manic and mixed episodes. This discrepancy
could be due to the followings. First, the STEP-BD study
collapsed all published clinical practice guidelines at the
time into a composite guideline as the “standard” for
guideline concordance or disconcordance. Second, both
sequenced treatment alternatives and therapeutic dos-
ages were considered in the STEP-BD study. Third, our
present survey was conducted in large-scale psychiatric
and general hospitals across mainland China. If strictly
followed the recommendations in the CANMAT and
ISBD guidelines, the disconcordant rate could be much
higher than 11.1%.
The probable factors predicting guidelines disconcor-
dance could be both physician-specific and patient-specific.
The practice type and experience of clinicians may be im-
portant factors affecting clinical decisions and guideline
concordance [7,21]. Those practitioners who did not com-
ply with guidelines might believe that those guidelines did
not address particular features of their clinical patient
populations [22]. As reported previously, only 3.4% pa-
tients with a mood disorder had ever seen a mental health
professional, 4.9% had ever sought a non-mental health
professional in mainland China [23]. The general practi-
tioners in general hospitals usually prescribe medication(s)
for patients with a mood disorder in mainland China. Be-
cause general practitioners have little or no training in
mental health, they are unable (and often unwilling) to
provide basic psychiatric services for those with a mood
disorder [23], which could be one plausible explanation
for the absence of psychotropic treatment (7.4%) and the
inappropriate use of antidepressants (1.9%) in this survey.
The finding of a mixed episode at study entry associ-
ated with increased risk for guidelines-disconcordance is
consistent with previous studies [18,24]. Mania (81%)
was more likely to be managed in accordance with
guidelines than depression (64%) or mixed episodes
(62%) [18]. The divergence from guidelines was mostly
noted for patients with hypomania, which was associated
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sence of psychotropic treatment, and/or inadequate dos-
age [20]. Since our study focused on the current episode
and did not make a distinction between hypomania and
mania, the previous diagnose(s) and the current subtype
of bipolar disorders could not be verified. Therefore, the
proportion of discorntant-treatments due to misdiagnosis
or correct diagnosis with inappropriate treatments is diffi-
cult to be determined. In contrast, a longer duration of
bipolar illness was associated with the decreased risk for
disconcordant treatments, suggesting that long-term ill-
ness could provide more opportunities for clinician(s)
to make a correct diagnosis and proper treatment.
The finding of a mood stabilizer(s) plus an antipsychotic(s)
as the most commonly prescribed pattern (more than
50%) in our study is consistent with a previous report that
polypharmacy for acute manic and mixed episodes was a
common phenomenon [24]. Since our study was cross-
sectional and retrospective, the role of the combination
therapy during the course of acute episode was unknown.
However, the validity of this practice is still debatable.
Some evidence from both clinical practice and random-
ized controlled trials showed that the addition of anti-
psychotic(s) to lithium or valproate was superior to
lithium or valproate alone, but there is not enough un-
ambiguous evidence that supports the combination
therapy of a mood stabilizer with an antipsychotic as a
general first-line treatment [12]. Considering a higher
frequency and/or greater severity of side effects associ-
ated with combination therapy relative to monotherapy,
a mood stabilizer(s) plus an antipsychotic(s) should be
reserved for severe mania or as a subsequent step for
mild to moderate mania [12]. Similarly, Post et al. re-
ported that complex medication regimens were required
to achieve a sustained response when monotherapy was
unsuccessful [25]. Thus delineating the clinical and bio-
logic correlates of individual response to combination
treatment could be one of clinical research priorities in
the future [25].
Several limitations of this study should be considered.
First, this study was carried out in 26 large-scale psychi-
atric and general hospitals across mainland China. They
are all located in the provincial capital cities or municipal-
ities and directly under the central governments’ control.
The current practice for the treatment of patients with
BPD in small and medium-sized cities, village or commu-
nity was not included in this study. Second, this study was
a cross-sectional and retrospective investigation based on
medical records, which did not allow us to study the
changes in the treatment regimes for patients with acute
manic and mixed episodes. Some psychotropic agents
could be the continuation from previous treatment re-
gimes for previous mood episodes. Therefore, some agents
might not be used specially for the recent manic andmixed episodes. Third, the studied demographics and
clinical characteristics were most patient-specific fac-
tors. Physician-specific factors such as age, education
level, and training experience were not available in the
present study, which was reported to affect prescribing
pattern and guideline concordance [7,21,22].
Conclusions
In mainland China, the guideline-disconcordant treatments
for patients with an acute hypomanic, manic or mixed
episode were not common (11.1%) under naturalistic
conditions. The absence of psychotropic treatment and
the inappropriate use of antidepressants were the major
factors for the disconcordance. The correlation between
guidelines disconcordance and physician-specific (physi-
cians from general hospitals) and patient-specific features
(a mixed episode at study entry and a shorter duration of
disease) factors suggest that in order to avoid improper
psychotropic treatments for an acute mania/hypomania/
mixed episode and to close the gap between treatment
guidelines and clinical practice in mainland China, con-
tinuing education to practitioners, especially those in
general hospitals, is necessary.
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